Liver Disease Diagnostics Market Size, Share & Trends Report

Liver Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy, Others), End-use (Hospital, Laboratories, Others), And Segment Forecasts, 2020 - 2027

  • Published Date: Jun, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-4-68038-693-6
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 80

Report Overview

The global liver disease diagnostics market size was valued at USD 29.3 billion in 2019 and is estimated to grow at a compound annual growth rate (CAGR) of 6.5% from 2020 to 2027. Rising prevalence of acute and chronic liver diseases is one of the major factors expected to drive the market for liver disease diagnostics. For instance, according to the WHO, in 2018, 841,080 new cases of liver cancer were reported globally and an estimated 781, 631 people died due to liver cancer. Rising initiatives undertaken by key players to develop highly sensitive and rapid tests to detect liver diseases in specific populations such as pregnant women and HIV-positive patients is anticipated to boost the market for liver disease diagnostics. For instance, in February 2019, Abbott received a CE mark for Determine HBsAg 2 test, a sensitive, easy-to-use, and rapid diagnostic test used for the detection of hepatitis B.

U.S liver disease diagnostics market size

Furthermore, increasing R&D of accurate diagnostic systems to improve early diagnosis and patient outcomes is expected to propel the growth of the market for liver disease diagnostics. In March 2020, F. Hoffmann-La Roche Ltd. was granted Breakthrough Device Designation for Elecsys GALAD score. Elecsys GALAD score was developed under Roche Diagnostics Liver Indication Program to improve diagnostic workflow and support clinicians by providing accurate information.

The presence of favorable reimbursement policies by Medicare, Medicaid, and other health insurance programs is expected to accelerate the market for liver disease diagnostics. The Medicare coverage policy in CodeMap, a leading source of reimbursement solutions, and Medicare compliance includes piccolo express liver panel plus developed by Abbott with a medicare reimbursement of USD 30.89.

In addition, the introduction of novel methods to diagnose diseases is likely to have a positive impact on the market for liver disease diagnostics. For instance, in December 2017, VITROS ALTV Slides, a new and novel method for the measurement of Alanine Aminotransferase (ALT) using dry slide technology was developed by Ortho Clinical Diagnostics. This novel method reduces the volume of sample requirement, increases sensitivity, and enhances precision performance.

Diagnosis Technique Insights

The imaging segment dominated the market and held a revenue share of 29.4% in 2019. This is attributed to the rising number of initiatives taken by key players in the market for liver disease diagnostics to develop advanced imaging techniques. Laboratory tests are carried out using urine, blood, and other fluid samples to diagnose the liver function. Whereas, imaging includes ultrasound, X-ray, Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, and others. Imaging is estimated to witness a significant CAGR of 6.9% during the forecast period.

In addition, the key players in the market for liver disease diagnostics are undertaking initiatives to support non-profit organizations to raise awareness and help physicians in detecting liver diseases. In January 2020, Echosens supported Fatty Liver Foundation (FLF) by providing FibroScan to help clinicians in detecting, monitoring, and preventing liver diseases.

End-use Insights

The hospitals segment held the largest revenue share of 45.5% in 2019 as the majority of patients rely on hospitals well-equipped with diagnostic testing devices. Hospitals provide optimal care to patients and enable early detection & diagnosis, thus boosting the growth of the market for liver disease diagnostics. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities.

The laboratories segment is projected to be the fastest growing segment in the liver disease diagnostics market over the forecast years. Various laboratories and institutes conduct awareness programs to diagnose hepatic organ disease. For instance, in December 2017, the Institute of Liver and Biliary Sciences collaborated with Mylan Laboratories to conduct screening and awareness programs. The aim was to provide quality screening and testing facilities for more than 1000 patients in Delhi. The program conducted tests such as Hepatitis B & C, Fibroscan, and ALT.

Global liver disease diagnostics market share

Regional Insights

North America dominated the market and held a revenue share of 43.1% in 2019, followed by Europe. High investments in R&D and presence of key players are some factors expected to be responsible for the growth of the market for liver disease diagnostics in the region. Furthermore, the presence of organizations that provide information regarding the diagnosis of diseases to patients is expected to fuel the growth of the market for liver disease diagnostics. One such organization is GetPalliativeCare.org that provides palliative care information related to diagnostic methods such as endoscopy, CT scan, and biopsy.

The market for liver disease diagnostics in the Asia Pacific is expected to grow at a significant rate during the forecast period. Increasing geriatric population and awareness about regular check-ups are contributing to the growth of the market for liver disease diagnostics in this region. Furthermore, regulatory approval of advanced technologies that can be integrated with imaging systems is estimated to drive regional growth. For instance, in August 2018, LiverMultiScan received clearance from Therapeutic Goods Administration (TGA) to diagnose patients with highly prevalent diseases in Australia such as NAFLD and NASH.

Key Companies & Market Share Insights

The key players are implementing multiple strategies for the development of innovative technologies to advance patient care. In August 2019, Boston Scientific Corporation acquired BTG plc to offer access to advanced technologies for better patient care. Some of the prominent players in the liver disease diagnostics market include:

  • Abbott

  • F. Hoffmann-La Roche Ltd.

  • Thermo Fisher Scientific Inc.

  • Randox Laboratories Ltd.

  • Boston Scientific Corporation

  • Laboratory Corporation of America Holdings

  • Fujifilm Corporation

  • Horiba Medical

  • Siemens Healthcare GmbH.

Liver Disease Diagnostics Market Report Scope

Report Attribute

Details

Market size value in 2020

USD 31.2 billion

Revenue forecast in 2027

USD 48.7 billion

Growth rate

CAGR of 6.5% from 2020 to 2027

Base year for estimation

2019

Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD Million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Diagnosis technique, end use, region

Regional scope

North America; Europe; Asia-Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K., France; Italy; Spain; Russia; Japan; China; India; Australia; Singapore; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE

Key companies profiled

Abbott; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Randox Laboratories Ltd.; Boston Scientific Corporation; Laboratory Corporation of America Holdings; Fujifilm Corporation; Horiba Medical; Siemens Healthcare GmbH

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global liver disease diagnostics market report on the basis of diagnosis technique, end use, and region:

  • Diagnosis Technique Outlook (Revenue, USD Million, 2016 - 2027)

    • Imaging

    • Laboratory tests

    • Endoscopy

    • Biopsy

    • Others

  • End-Use Outlook (Revenue, USD Million,2016 - 2027)

    • Hospitals

    • Laboratories

    • Others

  • Regional Outlook (Revenue, USD Million,2016 - 2027)

    • North America

      • U.S

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Singapore

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • Saudi Arabia

      • South Africa

      • UAE

Frequently Asked Questions About This Report

Pricing & Purchase Options

Service Guarantee

  • Quality assurance

    Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Information security

    Confidentiality

    We are in compliance with GDPR & CCPR norms. All interactions are confidential.

  • grand view research PCI DSS complaint grand view research gdpr verified
  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities